Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer

The epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitors (TKIs) have shown remarkable benefits in non-small cell lung cancer (NSCLC) patients with drug-sensitive mutations in the EGFR gene. Responsive patients are usually continuously prescribed with TKIs until disease progre...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Wang, Hsian-Yu, Chang, Yu-Ling, Cheng, Chun-Chun, Chao, Min-Wu, Lin, Su-I, Pan, Shiow-Lin, Hsu, Chih-Cheng, Liu, Tsang-Wu, Cheng, Han-Chin, Tseng, Ching-Ping, Liu, Shih-Jen, Tsai, Hui-Ju, Chang, Hsing-Yi, Hsu, John T.-A.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5349885/
https://ncbi.nlm.nih.gov/pubmed/27835586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13185
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki